X Monnet1, B Lamia, N Anguel, C Richard, G Bonmarchand, J L Teboul. 1. Service de Réanimation Médicale, CHU de Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris XI, 78 rue du Général Leclerc, 94270, le Kremlin-Bicêtre, France. xavier.monnet@bct.aphp.fr
Abstract
OBJECTIVE: Because recombinant human activated protein C (rhAPC) reduces NO production during sepsis, it could improve the vascular tone. We tested whether rhAPC reduces the dose of norepinephrine required to maintain mean arterial pressure (MAP) in septic shock patients. DESIGN AND SETTING: Retrospective study in intensive care unit of two university hospitals. PATIENTS: Twenty-two septic shock patients with at least two organ failures were retrospectively investigated for MAP and the required dose of norepinephrine before and 24 h after rhAPC administration. A control group of 22 septic shock patients with at least two organ failures who did not receive rhAPC was matched on age, SAPS II, MAP, and norepinephrine dose at the time of the theoretical start of rhAPC. MEASUREMENTS AND RESULTS: The MAP remained stable and similar in the two groups (86+/-16 vs. 89+/-9 mmHg at 24 h). The required dose of norepinephrine increased in the control group (+38%, from -41% to +38%) but decreased in the treated group (-33%, from -74% to +11%). CONCLUSIONS: rhAPC rapidly improved the vascular tone in septic shock patients as assessed by a decrease in the norepinephrine dose required to maintain arterial pressure.
OBJECTIVE: Because recombinant human activated protein C (rhAPC) reduces NO production during sepsis, it could improve the vascular tone. We tested whether rhAPC reduces the dose of norepinephrine required to maintain mean arterial pressure (MAP) in septic shockpatients. DESIGN AND SETTING: Retrospective study in intensive care unit of two university hospitals. PATIENTS: Twenty-two septic shockpatients with at least two organ failures were retrospectively investigated for MAP and the required dose of norepinephrine before and 24 h after rhAPC administration. A control group of 22 septic shockpatients with at least two organ failures who did not receive rhAPC was matched on age, SAPS II, MAP, and norepinephrine dose at the time of the theoretical start of rhAPC. MEASUREMENTS AND RESULTS: The MAP remained stable and similar in the two groups (86+/-16 vs. 89+/-9 mmHg at 24 h). The required dose of norepinephrine increased in the control group (+38%, from -41% to +38%) but decreased in the treated group (-33%, from -74% to +11%). CONCLUSIONS: rhAPC rapidly improved the vascular tone in septic shockpatients as assessed by a decrease in the norepinephrine dose required to maintain arterial pressure.
Authors: James H Finigan; Steven M Dudek; Patrick A Singleton; Eddie T Chiang; Jeffrey R Jacobson; Sara M Camp; Shiu Q Ye; Joe G N Garcia Journal: J Biol Chem Date: 2005-02-14 Impact factor: 5.157
Authors: Aurélie Bourgoin; Marc Leone; Anne Delmas; Franck Garnier; Jacques Albanèse; Claude Martin Journal: Crit Care Med Date: 2005-04 Impact factor: 7.598
Authors: G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher Journal: N Engl J Med Date: 2001-03-08 Impact factor: 91.245
Authors: Jean-Louis Vincent; Derek C Angus; Antonio Artigas; Andre Kalil; Bruce R Basson; Hassan H Jamal; Gerald Johnson; Gordon R Bernard Journal: Crit Care Med Date: 2003-03 Impact factor: 7.598
Authors: Andre C Kalil; Susette M Coyle; John Y Um; Steven P LaRosa; Mary Ann Turlo; Steve E Calvano; David P Sundin; David R Nelson; Stephen F Lowry Journal: Shock Date: 2004-03 Impact factor: 3.454
Authors: Jeppe Sylvest Nielsen; Anders Larsson; Thomas Rix; Rasmus Nyboe; Jakob Gjedsted; Jan Krog; Thomas Ledet; Else Tønnesen Journal: Intensive Care Med Date: 2007-04-25 Impact factor: 17.440
Authors: B Levy; S Collin; N Sennoun; N Ducrocq; A Kimmoun; P Asfar; P Perez; F Meziani Journal: Intensive Care Med Date: 2010-09-23 Impact factor: 17.440
Authors: Edward Kerschen; Irene Hernandez; Mark Zogg; Shuang Jia; Martin J Hessner; Jose A Fernandez; John H Griffin; Claudia S Huettner; Francis J Castellino; Hartmut Weiler Journal: J Clin Invest Date: 2010-08-16 Impact factor: 14.808
Authors: A Vieillard-Baron; V Caille; C Charron; G Belliard; P Aegerter; B Page; F Jardin Journal: Intensive Care Med Date: 2009-06-16 Impact factor: 17.440
Authors: Marc O Maybauer; Dirk M Maybauer; John F Fraser; Csaba Szabo; Martin Westphal; Levente Kiss; Eszter M Horvath; Yoshimitsu Nakano; David N Herndon; Lillian D Traber; Daniel L Traber Journal: Crit Care Date: 2010-11-26 Impact factor: 9.097